Holistic metabonomic profiling of urine affords potential early diagnosis for bladder and kidney cancers

Metabolomics

Volumn 9, Issue 1, 2013, Pages 119-129

  Huang, Zhenzhen ^a   Chen, Yongjing ^a   Hang, Wei ^a   Gao, Yao ^a   Lin, Lin ^a   Li, Daniel Y ^b   Xing, Jinchun ^c   Yan, Xiaomei ^a  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Xiamen First Hospital   (China)

Author keywords

Bladder cancer; Early diagnosis; Kidney cancer; Metabonomics; Urine

Indexed keywords

ACEGLUTAMIDE; BETAINE; CARNITINE; HIPPURIC ACID; PHENYLACTEYLGLUTAMINE; TAURINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; KIDNEY CANCER; MALE; MASS SPECTROMETRY; METABOLOMICS; METABONOMICS; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; URINALYSIS; VALIDATION PROCESS;

EID: 84872651699     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-012-0433-5     Document Type: Article

References (45)

1. An, Z. L., Chen, Y. H., Zhang, R. P., Song, Y. M., Sun, J. H., He, J. M., et al. (2010). Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. Journal of Proteome Research, 9(8), 4071-4081. doi: 10. 1021/pr100265g.
2. Beckonert, O., Monnerjahn, J., Bonk, U., & Leibfritz, D. (2003). Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR in Biomedicine, 16(1), 1-11. doi: 10. 1002/nbm. 797.
3. Bruce, S. J., Jonsson, P., Antti, H., Cloarec, O., Trygg, J., Marklund, S. L., et al. (2008). Evaluation of a protocol for metabolic profiling studies on human blood plasma by combined ultra-performance liquid chromatography/mass spectrometry: from extraction to data analysis. Analytical Biochemistry, 372(2), 237-249. doi: 10. 1016/j. ab. 2007. 09. 037.
4. Bylesjö, M., Rantalainen, M., Cloarec, O., Nicholson, J. K., Holmes, E., & Trygg, J. (2006). OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. Journal of Chemometrics, 20(8-10), 341-351. doi: 10. 1002/cem. 1006.
5. Catchpole, G., Platzer, A., Weikert, C., Kempkensteffen, C., Johannsen, M., Krause, H., et al. (2011). Metabolic profiling reveals key metabolic features of renal cell carcinoma. Journal of Cellular and Molecular Medicine, 15(1), 109-118. doi: 10. 1111/j. 1582-4934. 2009. 00939. x.
6. Chen, J., Wang, W., Lv, S., Yin, P., Zhao, X., Lu, X., et al. (2009). Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Analytica Chimica Acta, 650(1), 3-9. doi: 10. 1016/j. aca. 2009. 03. 039.
7. Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., & Di Leo, A. (2007). Metabolomics: Available results, current research projects in breast cancer, and future applications. Journal of Clinical Oncology, 25(19), 2840-2846. doi: 10. 1200/Jco. 2006. 09. 7550.
8. Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature, 440(7087), 1073-1077. doi: 10. 1038/nature04648.
9. Cohen, H. T., & McGovern, F. J. (2005). Renal-cell carcinoma. New England Journal of Medicine, 353(23), 2477-2490. doi: 10. 1056/NEJMra043172.
10. Cubbon, S., Antonio, C., Wilson, J., & Thomas-Oates, J. (2010). Metabolomic applications of HILIC-LC-MS. Mass Spectrometry Reviews, 29(5), 671-684. doi: 10. 1002/Mas. 20252.
11. Cubbon, S., Bradbury, T., Wilson, J., & Thomas-Oates, J. (2007). Hydrophilic interaction chromatography for mass spectrometric metabonomic studies of urine. Analytical Chemistry, 79(23), 8911-8918. doi: 10. 1021/ac071008v.
12. Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342-348. doi: 10. 1038/35077213.
13. Gamagedara, S., Shi, H., & Ma, Y. (2012). Quantitative determination of taurine and related biomarkers in urine by liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 402(2), 763-770. doi: 10. 1007/s00216-011-5491-4.
14. Gika, H. G., Theodoridis, G. A., & Wilson, I. D. (2008). Hydrophilic interaction and reversed-phase ultra-performance liquid chromatography TOF-MS for metabonomic analysis of Zucker rat urine. Journal of Separation Science, 31(9), 1598-1608. doi: 10. 1002/jssc. 200700644.
15. Gika, H. G., Theodoridis, G. A., Wingate, J. E., & Wilson, I. D. (2007). Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: Application to human urine. Journal of Proteome Research, 6(8), 3291-3303. doi: 10. 1021/Pr070183p.
16. Greene, F. L., Page, D. L., Fleming, I. D., Fritz, A., Balch, C. M., Haller, D. G., et al. (Eds.). (2002). AJCC cancer staging manual (6th ed.). New York: Springer.
17. Issaq, H. J., Nativ, O., Waybright, T., Luke, B., Veenstra, T. D., Issaq, E. J., et al. (2008). Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. The Journal of Urology, 179(6), 2422-2426. doi: 10. 1016/j. juro. 2008. 01. 084.
18. Kim, K., Aronov, P., Zakharkin, S. O., Anderson, D., Perroud, B., Thompson, I. M., et al. (2009). Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Molecular and Cellular Proteomics, 8(3), 558-570. doi: 10. 1074/mcp. M800165-MCP200.
19. Kind, T., & Fiehn, O. (2010). Advances in structure elucidation of small molecules using mass spectrometry. Bioanalytical Reviews, 2(1), 23-60. doi: 10. 1007/s12566-010-0015-9.
20. Kind, T., Tolstikov, V., Fiehn, O., & Weiss, R. H. (2007). A comprehensive urinary metabolomic approach for identifying kidney cancer. Analytical Biochemistry, 363(2), 185-195. doi: 10. 1016/j. ab. 2007. 01. 028.
21. Kutikov, A., Egleston, B. L., Wong, Y.-N., & Uzzo, R. G. (2010). Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. Journal of Clinical Oncology, 28(2), 311-317. doi: 10. 1200/jco. 2009. 22. 4816.
22. Lin, L., Hang, W., Huang, Z. Z., Gao, Y., Yan, X. M., & Xing, J. C. (2011). LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. Journal of Proteome Research, 10(3), 1396-1405. doi: 10. 1021/pr101161u.
23. Linehan, W. M., Walther, M. M., & Zbar, B. (2003). The genetic basis of cancer of the kidney. Journal of Urology, 170(6), 2163-2172. doi: 10. 1097/01. ju. 0000096060. 92397. ed.
24. McClinton, S., Moffat, L. E., Horrobin, D. F., & Manku, M. S. (1991). Abnormalities of essential fatty acid distribution in the plasma phospholipids of patients with bladder cancer. British Journal of Cancer, 63(2), 314-316.
25. Michael, A., & Pandha, H. S. (2003). Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncology, 4(4), 215-223. doi: 10. 1016/S1470-2045(03)01044-1.
26. Mitra, A. P., & Cote, R. J. (2010). Molecular screening for bladder cancer: progress and potential. Nature Reviews Urology, 7(1), 11-20. doi: 10. 1038/nrurol. 2009. 236.
27. Mohammed, S. I., & Rahman, M. (2008). Proteomics and genomics of urinary bladder cancer. Proteomics Clinical Application, 2(9), 1194-1207. doi: 0. 1002/prca. 200780089.
28. Moreno, A., Rey, M., Montane, J. M., Alonso, J., & Arús, C. (1993). 1H NMR spectroscopy of colon tumors and normal mucosal biopsies; elevated taurine levels and reduced polyethyleneglycol absorption in tumors may have diagnostic significance. NMR in Biomedicine, 6(2), 111-118. doi: 10. 1002/nbm. 1940060202.
29. Morrissey, J. J., London, A. N., Luo, J. Q., & Kharasch, E. D. (2010). Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clinic Proceedings, 85(5), 413-421. doi: 10. 4065/mcp. 20090709.
30. Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999). 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 29(11), 1181-1189. doi: 10. 1080/004982599238047.
31. Ott, O. J., Rödel, C., Weiss, C., Wittlinger, M., St. Krause, F., Dunst, J., et al. (2009). Radiochemotherapy for bladder cancer. Clinical Oncology, 21(7), 557-565. doi: 10. 1016/j. clon. 2009. 05. 005.
32. Paik, M. J., Kim, J. W., Lee, G., Moon, S. M., Park, M. J., Hong, S. K., et al. (2010). Metabolomic screening and star pattern recognition by urinary amino acid profile analysis from bladder cancer patients. Metabolomics, 6(2), 202-206. doi: 10. 1007/s11306-010-0199-6.
33. Pasikanti, K. K., Esuvaranathan, K., Ho, P. C., Mahendran, R., Kamaraj, R., Wu, Q. H., et al. (2010). Noninvasive urinary metabonomic diagnosis of human bladder cancer. Journal of Proteome Research, 9(6), 2988-2995. doi: 10. 1021/Pr901173v.
34. Poynard, T., Halfon, P., Castera, L., Munteanu, M., Imbert-Bismut, F., Ratziu, V., et al. (2007). Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clinical Chemistry, 53(9), 1615-1622. doi: 10. 1373/clinchem. 2007. 085795.
35. Qin, F., Zhao, Y. Y., Sawyer, M. B., & Li, X. F. (2008). Hydrophilic interaction liquid chromatography-tandem mass spectrometry determination of estrogen conjugates in human urine. Analytical Chemistry, 80(9), 3404-3411. doi: 10. 1021/ac702613k.
36. Quackenbush, J. (2006). Microarray analysis and tumor classification. New England Journal of Medicine, 354(23), 2463-2472. doi: 10. 1056/NEJMra042342.
37. Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011). Cancer statistics, 2011. CA: A Cancer Journal for Clinicians, 61(4), 212-236. doi: 10. 3322/caac. 20121.
38. Slupsky, C. M., Steed, H., Wells, T. H., Dabbs, K., Schepansky, A., Capstick, V., et al. (2010). Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clinical Cancer Research, 16(23), 5835-5841. doi: 10. 1158/1078-0432. ccr-10-1434.
39. Spratlin, J. L., Serkova, N. J., & Eckhardt, S. G. (2009). Clinical applications of metabolomics in oncology: A review. Clinical Cancer Research, 15(2), 431-440. doi: 10. 1158/1078-0432. ccr-08-1059.
40. Srivastavaa, S., Roy, R., Singh, S., Kumar, P., Dalela, D., Sankhwarc, S. N., et al. (2010). Taurine-a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomarkers, 6(1), 11-20. doi: 10. 3233/CBM-2009-0115.
41. Theodoridis, G., Gika, H. G., & Wilson, I. D. (2011). Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies. Mass Spectrometry Reviews, 30(5), 884-906. doi: 10. 1002/mas. 20306.
42. Umetrics, A. (2005). User's guide to SIMCA-P, SIMCA-P+ version 12. 0.
43. Wiklund, S., Johansson, E., Sjostrom, L., Mellerowicz, E. J., Edlund, U., Shockcor, J. P., et al. (2008). Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Analytical Chemistry, 80(1), 115-122. doi: 10. 1021/Ac0713510.
44. Yang, Q., Shi, X., Wang, Y., Wang, W., He, H., Lu, X., et al. (2010). Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. Journal of Separation Science, 33(10), 1495-1503. doi: 10. 1002/jssc. 200900798.
45. Yin, P., Wan, D., Zhao, C., Chen, J., Zhao, X., Wang, W., et al. (2009). A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Molecular BioSystems, 5(8), 868-876. doi: 10. 1039/b820224a.